Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
25/05/2026 08:24
May 25 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC'S PARTNER EISAI PRESENTS SALES SIMULATION OF POTENTIAL FUTURE SALES OF LEQEMBI AT ITS INVESTOR RELATIONS DAY ACCORDING TO EISAI'S SIMULATION, LEQEMBI SALES WILL REACH AROUND JPY 300 BILLION FOR COMPANY'S FY 2028 Source text: ID:nWkr81Jn4b Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln